The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Response to a Monovalent 2009 Influenza A (H1N1) Vaccine
Open accessAbstract
BACKGROUND: A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years. A safe and effective vaccine is needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia. METHODS: We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 subjects, equally divided into two age groups (<50 years and >or=50 years), were enrolled and underwent randomization to receive either 15 microg or 30 microg of hemagglutinin antigen by intramuscular injection. We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination. The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer. RESULTS: By day 21 after the first dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects (95.0%) who received the 15-microg dose and in 106 of 119 subjects (89.1%) who received the 30-microg dose. A similar result was observed after the second dose of vaccine. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 56.3% of subjects, and systemic symptoms (e.g., headache) by 53.8% of subjects after each dose. Nearly all events were mild to moderate in intensity. CONCLUSIONS: A single 15-microg dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions. (ClinicalTrials.gov number, NCT00938639).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garten, R. J., Davis, C. T., Russell, C. A., Shu, B., Lindstrom, S., Balish, A., Sessions, W. M., Xu, X., Skepner, E., Deyde, V., et al. (2009) · Science · doi:10.1126/science.1176225 · Cited by 2,499
Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus
Hancock, K., Veguilla, V., Lu, X., Zhong, W., Butler, E. N., Sun, H., Liu, F., Dong, L., DeVos, J. R., Gargiullo, P. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906453 · Cited by 1,259
Rowe, T., Abernathy, R. A., Hu-Primmer, J., Thompson, W. W., Lu, X., Lim, W., Fukuda, K., Cox, N. J., & Katz, J. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.937-943.1999 · Cited by 811
Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine
Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., & Wolff, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055778 · Cited by 698
Historical Perspective — Emergence of Influenza A (H1N1) Viruses
Zimmer, S. M., & Burke, D. S. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0904322 · Cited by 405
Neuzil, K. M., Jackson, L. A., Nelson, J., Klimov, A., Cox, N., Bridges, C. B., Dunn, J., DeStefano, F., & Shay, D. (2006) · The Journal of Infectious Diseases · doi:10.1086/507309 · Cited by 191
Reflections on the 1976 swine flu vaccination program
Sencer, D. J., & Millar, J. D. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1201.051007 · Cited by 163
Summary of Clinical Trials of Influenza Virus Vaccines in Adults
Parkman, P. D., Hopps, H. E., Rastogi, S. C., et al. (1977) · The Journal of Infectious Diseases · doi:10.1093/infdis/136.supplement_3.s722 · Cited by 108
Public Health and Medical Responses to the 1957-58 Influenza Pandemic
Henderson, D. A., Courtney, B., Inglesby, T. V., Toner, E. S., & Nuzzo, J. B. (2009) · Biosecurity and Bioterrorism Biodefense Strategy Practice and Science · doi:10.1089/bsp.2009.0729 · Cited by 104
Immunization With Trivalent Inactivated Influenza Vaccine in Partially Immunized Toddlers
Englund, J. A., Walter, E. B., GBADEBO, A., et al. (2006) · PEDIATRICS · doi:10.1542/peds.2006-0201 · Cited by 97
Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine
Talbot, H. K., Keitel, W. A., Cate, T. R., Treanor, J. J., Campbell, J. D., Brady, R. C., Graham, I. L., Dekker, C. L., Ho, D. Y., Winokur, P. L., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.05.024 · Cited by 35
Self-citationKuehn, B. M. (2009) · JAMA · doi:10.1001/jama.2009.1049 · Cited by 6
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Olsen, S. J., Karron, R. A., Jernigan, D. B., & Bresee, J. S. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6505a1 · Cited by 593
The 2009 A (H1N1) influenza virus pandemic: A review
Girard, M. P., Tam, J. S., Assossou, O. M., & Kieny, M. P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.05.031 · Cited by 488
Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454
Metadata
- Authors
- Greenberg, M. E., Lai, M. H., Hartel, G. F., Wichems, C. H., Gittleson, C., Bennet, J., Dawson, G., Hu, W., Leggio, C., Washington, D., & Basser, R. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2405-2413
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170155793
- Cited by
- 492
- References
- 12
- FWCI
- 72.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.